【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 格隆汇10月11日｜加多宝集团突然发布声明，声称拥有王老吉海外商标所有权。而此前9月30日，广州 王老吉大健康产业有限公司(下称"王老吉大健康公司")则指责加多宝属于恶意抢注，双方围绕海外商标 归属展开新一轮攻防战。据悉，万捷有限公司为加多宝集团海外离岸关联公司。天眼查App显示，"王 老吉"已被多方申请注册为商标，国际分类包括医药、饲料种籽、方便食品等，申请人包括万捷有限公 司、新郑市某饲料厂等。当前上述商标多已被驳回。此外，广州白云山(600332)医药集团股份有限公司 已申请注册多枚"王老吉"商标，当前商标状态多为已注册。 (责任编辑：宋政 HN002) ...

据报道，10月10日，加多宝集团突然发布声明，声称拥有王老吉海外商标所有权。而此前9月30日，广 州王老吉大健康产业有限公司（下称"王老吉大健康公司"）则指责加多宝属于恶意抢注，双方围绕海外 商标归属展开新一轮攻防战。据悉，万捷有限公司为加多宝集团海外离岸关联公司。天眼查App显 示，"王老吉"已被多方申请注册为商标，国际分类包括医药、饲料种籽、方便食品等，申请人包括万捷 有限公司、新郑市某饲料厂等。当前上述商标多已被驳回。此外，广州白云山医药集团股份有限公司已 申请注册多枚"王老吉"商标，当前商标状态多为已注册。 ...

近日，广药集团跟加多宝集团再次因为"王老吉"这个商标撕了起来，只是，这一次连个热搜都没蹭上。这背后，跟凉茶市场近年不太景气也有一定关系。 海外"王老吉"之争 10月10日，加多宝在自己的公众号上发布了关于海外"王老吉"商标的所有权声明，这是短短一旬时间里，加多宝第二次发公众号，以维护自己对于"王老 吉"海外所有权正统地位的维护。 在这期间，广药王老吉方也在其公众号：王老吉Walovi也回了一条严正声明称，广州王老吉大健康产业在全球100多个国家和地区完成了"王老 吉""Walovi"商标的注册，加多宝的表述是对商标法的误读等，是妨碍王老吉发展海外业务。 没想到，都2025年了还能看到双方因为商标继续打官司。不过，也很好理解，毕竟红牛的商标已经八年了还没争出个所以然，这样看来王老吉和加多宝的 商标之争，未来还有的拉扯，只是这次换了场地，双方更多是在大陆以外的市场一较高下了。 引发这次商标之争，加多宝集团方面有不可推卸的责任。 海外王老吉的品牌是由王泽邦的后人注册，而后授权给加多宝集团。如果有电影发烧友看过《胭脂扣》，那里面有句台词：可乐，外国的王老吉。可见王 老吉品牌的历史悠久以及对广大消费者的影响。但在双方进 ...

"王老吉"商标大战硝烟再起。10月10日，加多宝集团突然发布声明，声称拥有王老吉海外商标所有权。 而此前9月30日，广州王老吉大健康产业有限公司则指责加多宝属于恶意抢注，双方围绕海外商标归属 展开新一轮攻防战。 从声明来看，双方对于海外王老吉商标归属各执一词。在今日发布的声明中，加 多宝集团称20世纪90年代从王老吉后人手中取得凉茶秘方及海外王老吉商标使用权，并在2000年代合法 取得海外王老吉商标所有权，已经在全球60个主要国家和地区注册了王老吉商标，并称近期市场流传的 海外"王老吉"品牌权益的相关言论不实，将采取法律手段保护权益。 而在9月30日发布的公告中，王老 吉大健康公司则称王老吉商标所有人为广州白云山医药集团股份有限公司，并表示已在全球100多个国 家和地区完成"王老吉""WALOVI"系列商标注册。并指责加多宝集团通过海外离岸关联公司万捷有限公 司在全球多地恶意注册，干扰了公司正常拓展海外业务。 ...

【文/王力 编辑/周毅】 在主营业务持续下滑、现金流告急的危机时刻，白云山（600332.SH，00874.HK）却选择了一场7.49亿元的收购生意。9月26日，这家老牌医药巨头宣布收购 南京医药（600713.SH）11.04%股权，一举跃升为后者第二大股东。 然而，这笔看似雄心勃勃的战略投资，却难掩白云山自身深陷泥潭的窘境:2024年净利润暴跌30%创七年最低，核心产品"国产伟哥"金戈营收失速，王牌产品 王老吉贴牌乱象不止。而作为药企，研发投入大幅缩水至销售费用的十分之一，经营性现金流同步恶化，2025年上半年达负33.97亿元，同比暴跌66.79%。 值得注意的是，在"造血"功能严重衰竭之际，白云山掏出真金白银进行并购。这场交易究竟是困境突围的战略转机,还是病急乱投医的豪赌值得资本市场深 思。 7.5亿买下区域龙头席位:白云山的华东战略图谋 白云山这笔交易的核心标的南京医药，是一家具有相当分量的区域性医药流通龙头。根据股份转让合同,白云山旗下的广药二期基金将以5.18元/股的价格， 从Alliance Healthcare Asia Pacific Limited手中接盘1.45亿股非限售股份，交易总价 ...

9月28日晚间，南京医药（600713）披露关于签订《战略投资协议》的公告。 公司与广州白云山医药集团股份有限公司（以下简称"白云山"）及广州广药股权投资合伙企业（有限合 伙）（以下简称"广药二期基金"）签署《战略投资协议》。 目前，南京医药股票价格为4.88元/股，与现价相比，转让价格略有溢价。 白云山位于广州，公司是A+H上市公司，目前市值约413亿元。 公司主要从事：（1）中西成药、化学原料药、天然药物、生物医药、化学原料药中 间体的研究开发、 制造与销售；（2）西药、中药和医疗器械的批发、零售和进出口业务；（3） 大健康产品的研发、生 产与销售；及（4）医疗服务、健康管理、养生养老等健康产业投资等。 白云山是南派中药的集大成者，大南药板块主要为医药制造业务，下属共有 27 家医药制造企业与机 构，从事中西成药、化学原料药、化学原料 药中间体、生物医药和天然药物等的研发、制造与销售。 大健康板块主要为饮料、食品、保健品等产品的生产、研发与销售，主要从事的企业包括本公司下属子 公司王老吉大健康公司及王老吉药业等。 大商业板块主要为医药流通业务，包括医药产品、医疗器械、保健品等的批发、零售与进出口业务，主 ...

那些扎根传统行业的蓝筹股、白马股，比如白酒、银行、家电领域的龙头，都被归为 "老登" 股。 而像人工智能、芯片、机器人这些前沿科技赛道的公司，就被叫做 "小登" 股。 不知道从啥时候起，股市里多了 "老登""小登" 这两个说法。 原本 "老登" 是调侃思维老派的中老年人，现在却成了一类股票的标签。 曾经稳稳占据 "股王" 位置的贵州茅台，股价居然被 AI 赛道的股票超过了。 这事儿一出来，不少人开始议论，难道那些大家熟悉的 "老股" 真要不行了？ 可像白云山这样的传统企业，却在悄悄搞创新，这又给市场带来了不一样的思考。 "老登" 股和 "小登" 股，现在分得特别清 这两类股票的表现，最近差得不是一点半点。 拿 "老登" 股的代表贵州茅台来说，曾经多风光啊，2021 年股价最高冲到过 2627.88 元，总市值一度超 3 万亿元。 可到了今年 9 月 22 日收盘，茅台股价跌到了 1453.35 元，还走出了罕见的六连阴，总市值只剩 1.82 万 亿元。 再看 "小登" 股里的寒武纪，反差特别明显。 受国产 AI 芯片需求增长、国产替代加速的利好影响，寒武纪股价今年一路涨。 8 月 27 日那天，它盘中股价甚至 ...

Core Insights - The Chinese traditional medicine industry is experiencing significant growth driven by favorable policies and increasing market demand, with the market size expected to reach 1.05 trillion yuan in 2024, a year-on-year increase of 11.6% [1][3] - The industry is facing two major opportunities: policy dividends and market explosion, with a focus on balancing tradition and innovation [3][21] Policy and Market Dynamics - The government has introduced several policies to support the development of the traditional Chinese medicine industry, including the "Opinions on Improving the Quality of Traditional Chinese Medicine" and the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry" [3][4] - The market demand for traditional Chinese medicine is increasing due to rising health awareness and spending among consumers, particularly in areas such as aging, sub-health management, and chronic disease treatment [3][17] Quality Control and Innovation - Leading companies are enhancing quality control across the entire supply chain, with examples like Tong Ren Tang establishing a traceability system for medicinal materials and Guangzhou Pharmaceutical Group utilizing blockchain technology [4][19] - Companies are focusing on product innovation and adapting traditional formulas to meet contemporary health needs, with a strong emphasis on maintaining quality through traditional methods [6][10] Digital Transformation and E-commerce - The integration of digital technologies is crucial for the pharmaceutical industry, with companies like JD Health playing a significant role in transforming traditional medicine through e-commerce and data analytics [13][14] - The shift towards online platforms is helping traditional medicine brands reach younger consumers and adapt to changing market dynamics [10][13] Global Expansion and Future Directions - The internationalization of traditional Chinese medicine is becoming a key growth area, with products being registered in numerous countries and regions, reflecting a growing global acceptance [15][19] - Companies are focusing on three main strategic directions: deepening research and development, expanding into the "Chinese medicine +" health ecosystem, and accelerating digital integration [15][21]

Core Viewpoint - The article discusses the growing trend of foreign individuals embracing Chinese health and wellness practices, particularly through the consumption of traditional Chinese herbal drinks and the adoption of Chinese dietary habits and exercises, leading to a cultural exchange and the rise of "ice Chinese style" beverages like Wang Laoji [2][9][28]. Group 1: Cultural Adoption - Foreign influencers are increasingly engaging with Chinese wellness philosophies, as evidenced by the popularity of topics like TCMforlife on social media platforms, which has garnered 800 million discussions [3]. - Many foreigners are experimenting with traditional Chinese cooking and drinks, such as making apple and red date water, and are enjoying simple dishes like tomato scrambled eggs, which have become part of their daily routines [5][6]. - The trend extends to physical activities, with foreigners practicing Tai Chi and Qigong, and even creating hybrid fitness routines that combine Eastern and Western practices [5][9]. Group 2: Reverse Cultural Export - As more foreigners travel to China and experience its culture, they are bringing back elements of Chinese wellness, such as herbal drinks, to their home countries, facilitating a reverse cultural exchange [7][10]. - The concept of "ice Chinese style" beverages is gaining traction globally, with Wang Laoji becoming synonymous with this trend, reflecting a shift in consumer preferences towards healthier, natural drinks [11][12]. Group 3: Market Trends - The global beverage market is witnessing a decline in carbonated drinks, with a 6.7% drop expected from July 2023 to June 2024, while the plant-based beverage sector is experiencing significant growth, with a nearly 10% compound annual growth rate from 2019 to 2024 [20][22]. - Wang Laoji has seen a 6.5 times increase in its overseas market scale over ten years, with a compound annual growth rate exceeding 25%, indicating strong international demand for its products [26][28]. Group 4: Brand Strategy - Wang Laoji is not just selling products but also promoting cultural values and lifestyles, as seen in its establishment of museums in the U.S. to bridge cultural exchanges [18]. - The brand has successfully localized its products for international markets, launching new variants with Western names and expanding its supply chain to various countries, enhancing its global presence [26][28].

Core Insights - The global beverage market is entering a new phase with the launch of Wanglaoji's international cans, representing a significant brand upgrade and the introduction of four new products that embody Eastern health philosophy [1][2]. Product Launch - Wanglaoji unveiled four new international can products: Roselle Pearl Red Classic, Bright Dawn Orange Sugar-Free, Glazed Gold Original, and Misty Blue Sparkling, designed to resonate with global consumers while reflecting Eastern aesthetics [2]. - The brand's new visual identity, WALOVI, aims for clear and effective global communication, ensuring easy recognition and memory [2]. Financial Performance - Wanglaoji's parent company, Baiyunshan, reported a revenue of 6.499 billion yuan for the first half of 2025, marking an 8.38% year-on-year increase, with both operating profit and net profit showing double-digit growth [3]. - The growth is attributed to enhanced product offerings, deeper collaboration with major restaurant platforms, and increased brand investment targeting younger consumers [3]. Market Position - Wanglaoji holds nearly 50% market share in the domestic plant beverage segment, leading the industry in brand growth rate and various key performance indicators [4]. - The global plant beverage market is experiencing rapid growth, with a compound annual growth rate of nearly 10% from 2019 to 2024, contrasting with a decline in the carbonated beverage market [4]. Global Expansion Strategy - Wanglaoji has signed partnerships with major platforms like Dazhong Dianping and Meituan to penetrate local consumption scenarios and reshape consumer habits globally [6]. - The international cans have been launched in major Chinese cities and are set to expand into Southeast Asia, North America, Europe, and Oceania [6]. Brand Philosophy - The brand emphasizes the importance of natural ingredients and health, aiming to establish a global presence with a unified image and product matrix that meets diverse consumer needs [5]. - Wanglaoji's international branding strategy aims to transform Eastern health philosophy into a recognizable global consumer symbol [7]. Market Trends - The demand for health-oriented beverages is reshaping the beverage category, with plant-based drinks gaining prominence [3][4]. - Emerging markets like Southeast Asia and the Middle East are identified as new growth areas, with Southeast Asia's plant beverage growth rate reaching 25% in 2023 [6].